ligands acting on targets

15(R)-17-phenyl trinor Prostaglandin F2α ethyl amide an isomer of bimatoprost, characterized by an inverted (β) hydroxyl group at C-15. While this isomer has not been characterized, the comparable inversion of 15-hydroxyl groups, from (S) to (R), on

15(R)-17-phenyl trinor PGF2α is the 15-epi, or unnatural" isomer of the bimatroprost metabolite 17-phenyl trinor PGF2α. It has much diminished FP receptor-mediated activity, which is generally 1.5 to 2 logs less than the 15(S)-isomer. In glaucoma"

15(R)-17-phenyl trinor PGF2α is the 15-epi, or unnatural" isomer of the bimatroprost metabolite 17-phenyl trinor PGF2α. It has much diminished FP receptor-mediated activity, which is generally 1.5 to 2 logs less than the 15(S)-isomer. In glaucoma"

15(R)-Bimatoprost isopropyl ester is a latanoprost-related isomer containing both a double bond at 13,14 and an inverted (β) hydroxyl group at C-15. 15(S)-17-phenyl trinor PGF2α and 15(R)-17-phenyl trinor PGF2α IC50 values were determined to be 0.71

15(R)-Bimatoprost isopropyl ester is a latanoprost-related isomer containing both a double bond at 13,14 and an inverted (β) hydroxyl group at C-15. 15(S)-17-phenyl trinor PGF2α and 15(R)-17-phenyl trinor PGF2α IC50 values were determined to be 0.71

Lipoxin A4, 15-epi is an epimeric lipoxin A4 (catalog number sc-201060) analog that is more potent and metabolically stable than LXA4. Has been shown to exhibit anti-inflammatory properties and serves as a stop signal" to excessive leukocyte"

A stable analog of thromboxane A2 (TXA2). It is a thromboxane (TP) receptor antagonist and an inhibitor of thromboxane synthase. PTA2 inhibits U-46619-induced cat coronary artery constriction, U-46619-induced aggregation of human platelets (IC|50|=

A stable analog of thromboxane A2 (TXA2). It is a thromboxane (TP) receptor antagonist and an inhibitor of thromboxane synthase. PTA2 inhibits U-46619-induced cat coronary artery constriction, U-46619-induced aggregation of human platelets (IC|50|=

15(R)-15-methyl PGD2 is a surprisingly potent agonist at the DP2 receptor, being about 5 times more potent than PGD2 itself.4 15(R)-PGD2 has the potential to be produced endogenously as a natural ligand for DP2, unlike the synthetic 15-methyl

15(R)-15-methyl PGD2 is a surprisingly potent agonist at the DP2 receptor, being about 5 times more potent than PGD2 itself.4 15(R)-PGD2 has the potential to be produced endogenously as a natural ligand for DP2, unlike the synthetic 15-methyl

15(R)-PGE|1|is the unnatural" C-15 stereoisomer of PGE|1|. It is basically inactive biologically when compared to PGE|1|. It is a non-competitive inhibitor of 15-hydroxy PGDH with an IC50 of 189 μM."

15(R)-PGE|1|is the unnatural" C-15 stereoisomer of PGE|1|. It is basically inactive biologically when compared to PGE|1|. It is a non-competitive inhibitor of 15-hydroxy PGDH with an IC50 of 189 μM."